Peringatan Keamanan

Data regarding overdoses of lisocabtagene maraleucel are not readily available.L31588 Patients experiencing an overdose may be experience and increased risk and severity of severe infections, severe and prolonged cytopenia, hypogammaglobulinemia, cytokine release syndrome, and neurological toxicities.L31588 In the event of an overdose, initiate symptomatic and supportive measures.

Lisocabtagene maraleucel

DB16582

biotech approved

Deskripsi

Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel.A228493,L31588 Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.L31588

CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard therapy.A228493 However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking.A228493 Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.A228493

Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 L31583 and EC approval on 5 April 2022.L42210 It was later granted Health Canada approval on 6 May 2022.L43322

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Lisocabtagene maraleucel reaches a median Cmax of 23928.2 copies/µg with a median AUC of 213730 copies\*day/µg.A228478 The median time to peak expansion of T-cells was 12 days.A228478,L31588 Compared to non-responders, patients with a partial or complete response showed a 3.55-fold increase in Cmax and a 2.72-fold increase in AUC.A228478 Compared to non-responders, patients with a higher baseline tumor burden showed a 2.46-fold increase in Cmax, patients with cytokine release syndrome showed a 2.29-fold increase, and patients with neurological events showed a 3.34-fold increase.A228478

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

38 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Lisocabtagene maraleucel.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Lisocabtagene maraleucel.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Lisocabtagene maraleucel.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Lisocabtagene maraleucel.
Lidocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Quinisocaine.
Ambroxol The risk or severity of methemoglobinemia can be increased when Lisocabtagene maraleucel is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Lisocabtagene maraleucel is combined with Etrasimod.

Target Protein

B-lymphocyte antigen CD19 CD19

Referensi & Sumber

Artikel (PubMed)
  • PMID: 1725979
    Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y: Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol. 1991 Dec;69 ( Pt 6):411-22. doi: 10.1038/icb.1991.58.
  • PMID: 26497518
    Davies AM, Sutton BJ: Human IgG4: a structural perspective. Immunol Rev. 2015 Nov;268(1):139-59. doi: 10.1111/imr.12349.
  • PMID: 18064051
    Nimmerjahn F, Ravetch JV: Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008 Jan;8(1):34-47. doi: 10.1038/nri2206.
  • PMID: 32765524
    Leddon SA, Fettis MM, Abramo K, Kelly R, Oleksyn D, Miller J: The CD28 Transmembrane Domain Contains an Essential Dimerization Motif. Front Immunol. 2020 Jul 16;11:1519. doi: 10.3389/fimmu.2020.01519. eCollection 2020.
  • PMID: 24499671
    Vinay DS, Kwon BS: 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2014 Mar;47(3):122-9. doi: 10.5483/bmbrep.2014.47.3.283.
  • PMID: 1351920
    Howard FD, Moingeon P, Moebius U, McConkey DJ, Yandava B, Gennert TE, Reinherz EL: The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation. J Exp Med. 1992 Jul 1;176(1):139-45. doi: 10.1084/jem.176.1.139.
  • PMID: 32888407
    Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
  • PMID: 32670869
    Vitale C, Strati P: CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol. 2020 May 27;10:849. doi: 10.3389/fonc.2020.00849. eCollection 2020.

Contoh Produk & Brand

Produk: 4 • International brands: 1
Produk
  • Breyanzi
    Suspension • 120000000 cells • Intravenous • Canada • Approved
  • Breyanzi
    - • 35550000 cells/ml • Intravenous • EU • Approved
  • Breyanzi
    Injection, suspension; Kit • - • Intravenous • US • Approved
  • Breyanzi
    Injection, suspension; Kit • - • Intravenous • US • Approved
International Brands
  • Breyanzi — Bristol Myers Squibb

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul